What is the market cap of Cohance Lifesciences Ltd?

As of 06/02/2026, the market cap of Cohance Lifesciences Ltd stands at ₹12,986.20 Cr.

What is the PE and PB ratio of Cohance Lifesciences Ltd?

The PE and PB ratios of Cohance Lifesciences Ltd is 36.77 ratio and 115.25 ratio as of 06/02/2026.

What is the 52 week high and low of Cohance Lifesciences Ltd?

The 52 week high and low of Cohance Lifesciences Ltd is ₹1328 and ₹334.5 as of 06/02/2026.

How can I buy Cohance Lifesciences Ltd share?

You can easily buy Cohance Lifesciences Ltd shares on the Bajaj Broking platform by opening a Demat account and verifying your KYC documents online. There are no account opening charges for a Demat account with Bajaj Broking.

What determines a company’s share price?

A company’s share price is determined by supply and demand dynamics in the stock market. Factors influencing it include the company’s financial performance, earnings growth, revenue, and profitability, as well as broader economic conditions, market sentiment, and investor perception. Other determinants include sector trends, government policies, interest rates, and global events. Positive news or growth prospects can drive demand and raise the share price, while negative developments can push it lower. Analysts’ recommendations, institutional buying or selling, and technical factors such as trading volume also influence price movements. Ultimately, the share price reflects the market’s collective view of a company’s current and future value.

What is the “last sale,” “bid,” and “ask” price of Cohance Lifesciences Ltd?

The “last sale” is the most recent price at which a stock, like Cohance Lifesciences Ltd , was traded. The “bid” price represents the highest price buyers are willing to pay, while the “ask” price is the lowest price sellers are ready to accept. The difference between the bid and ask is known as the spread. Monitoring these prices helps investors understand market sentiment and liquidity. For example, a narrow spread indicates high liquidity and active trading, while a wide spread may suggest lower activity or higher volatility. These metrics are crucial for executing timely buy or sell orders in the stock market.

How to read share price charts for Cohance Lifesciences Ltd?

Share price charts display the historical price movement of Cohance Lifesciences Ltd , helping investors analyse trends, patterns, and potential entry or exit points. Charts typically show candlestick patterns, line graphs, or bar charts, representing open, high, low, and close prices. Key indicators include moving averages, support and resistance levels, and trading volume. Candlestick patterns can reveal bullish or bearish trends, while volume confirms the strength of price movements. Investors can use charts for technical analysis to assess momentum, predict short-term fluctuations, or complement fundamental analysis for long-term decisions. Understanding trends over daily, weekly, or monthly periods helps in making informed trading and investment choices.

What is volatility, and how does it affect share price movement for Cohance Lifesciences Ltd?

Volatility measures the degree of price fluctuations of a stock over time. High volatility indicates that Cohance Lifesciences Ltd share price can experience large swings in short periods, while low volatility suggests stable prices. Factors causing volatility include market sentiment, earnings announcements, global events, economic indicators, and industry news. High volatility can create opportunities for traders to profit from rapid price changes but also increases risk for long-term investors. Understanding volatility helps investors manage risk, set stop-loss limits, and determine the appropriate investment horizon based on their risk tolerance.

COHANCE LIFESCIENCES LTD

COHANCE

Small Cap | Pharmaceuticals

₹339.45

-17.34 (-4.85%)

‌

Stock price as on 06 Feb 2026 at 15:30 PM

Cohance lifesciences ltd share price update

As of the latest trading session, Cohance Lifesciences Ltd share price is currently at ₹339.45, which is down by ₹-17.34 from its previous closing. To...

Cohance Lifesciences Ltd stock performance

Today’s low

₹334.5

Today’s high

₹355

₹339.45

52 week low

₹334.5

52 week high

₹1,328

₹339.45

Open

₹353.00

Previous close

₹356.80

Share volume

9,40,350

Total traded value (Lakh)

₹3,192.01

Upper circuit

₹428.15

Lower circuit

₹285.45

Cohance Lifesciences Ltd fundamentals

Market cap (Cr)

₹12,986.20

P/E ratio (TTM)

36.77

Book value per share

₹115.25

Beta

0.72

Return on equity

12.51%

Earnings per share (TTM)

₹9.70

Dividend yield

Net profit/quarter (Cr)

₹94.29

Cohance Lifesciences Ltd financials

(Values in Cr)

Revenue

Net income

Particulars	Sep 25 (₹ value in crores)
Revenue	₹497.79
Operating expense	₹403.37
Net income	₹94.29
Net profit margin	18.94%
Earning per share	₹2.46
EBITDA	₹157.16
Effective tax rate	21.89%

Particulars	Jun 25 (₹ value in crores)
Revenue	₹483.58
Operating expense	₹417.54
Net income	₹52.57
Net profit margin	10.87%
Earning per share	₹1.38
EBITDA	₹109.20
Effective tax rate	25.99%

Particulars	Mar 25 (₹ value in crores)
Revenue	₹768.57
Operating expense	₹595.38
Net income	₹122.77
Net profit margin	15.97%
Earning per share	₹3.22
EBITDA	₹215.18
Effective tax rate	25.86%

Particulars	Dec 24 (₹ value in crores)
Revenue	₹284.27
Operating expense	₹188.55
Net income	₹83.67
Net profit margin	29.43%
Earning per share	₹3.29
EBITDA	₹128.72
Effective tax rate	24.77%

Particulars	Sep 24 (₹ value in crores)
Revenue	₹594.43
Operating expense	₹434.89
Net income	₹139.10
Net profit margin	23.4%
Earning per share	₹3.65
EBITDA	₹219.28
Effective tax rate	20.65%

Particulars	Mar 25 (₹ value in crores)
Revenue	₹2,504.43
Operating expense	₹1,903.43
Net income	₹491.18
Net profit margin	19.61%
Earning per share	₹12.89
EBITDA	₹833.27
Effective tax rate	24.44%

Particulars	Mar 24 (₹ value in crores)
Revenue	₹1,051.35
Operating expense	₹707.54
Net income	₹296.47
Net profit margin	28.19%
Earning per share	₹11.65
EBITDA	₹462.47
Effective tax rate	25.96%

Particulars	Mar 23 (₹ value in crores)
Revenue	₹1,330.08
Operating expense	₹795.24
Net income	₹432.60
Net profit margin	32.52%
Earning per share	₹16.99
EBITDA	₹635.24
Effective tax rate	25.33%

Particulars	Mar 22 (₹ value in crores)
Revenue	₹1,320.22
Operating expense	₹785.56
Net income	₹558.10
Net profit margin	42.27%
Earning per share	₹21.92
EBITDA	₹767.78
Effective tax rate	22.74%

Particulars	Mar 21 (₹ value in crores)
Revenue	₹1,009.72
Operating expense	₹609.97
Net income	₹308.65
Net profit margin	30.56%
Earning per share	₹12.12
EBITDA	₹454.76
Effective tax rate	25.44%

Particulars (annual)	Mar 25 (₹ value in crores)
Book value per share	₹66.64
Return on Equity (ROE)	12.5%
Return on Capital Employed (ROCE)	13.56%
Total debt to equity ratio	0.09
EBITDA margin	32.81%

Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	₹80.56
Return on Equity (ROE)	14.11%
Return on Capital Employed (ROCE)	18.69%
Total debt to equity ratio	0.04
EBITDA margin	40.22%

Particulars (annual)	Mar 23 (₹ value in crores)
Book value per share	₹68.16
Return on Equity (ROE)	25.21%
Return on Capital Employed (ROCE)	33.22%
Total debt to equity ratio	0.05
EBITDA margin	46.3%

Particulars (annual)	Mar 22 (₹ value in crores)
Book value per share	₹59.99
Return on Equity (ROE)	29.79%
Return on Capital Employed (ROCE)	40.62%
Total debt to equity ratio	0.09
EBITDA margin	48.55%

Particulars (annual)	Mar 21 (₹ value in crores)
Book value per share	₹46.38
Return on Equity (ROE)	35.78%
Return on Capital Employed (ROCE)	40.45%
Total debt to equity ratio	0.16
EBITDA margin	50.61%

Particulars (annual)	Mar 25 (₹ value in crores)
Book value per share	₹90.95
Return on Equity (ROE)	12.51%
Return on Capital Employed (ROCE)	15.94%
Total debt to equity ratio	0.04
EBITDA margin	38.09%

Particulars (annual)	Mar 24 (₹ value in crores)
Book value per share	₹79.67
Return on Equity (ROE)	15.7%
Return on Capital Employed (ROCE)	20.8%
Total debt to equity ratio	0.04
EBITDA margin	43.99%

Particulars (annual)	Mar 23 (₹ value in crores)
Book value per share	₹68.72
Return on Equity (ROE)	26.46%
Return on Capital Employed (ROCE)	34.28%
Total debt to equity ratio	0.05
EBITDA margin	47.76%

Particulars (annual)	Mar 22 (₹ value in crores)
Book value per share	₹59.74
Return on Equity (ROE)	43.17%
Return on Capital Employed (ROCE)	51.45%
Total debt to equity ratio	0.09
EBITDA margin	58.33%

Particulars (annual)	Mar 21 (₹ value in crores)
Book value per share	₹41.84
Return on Equity (ROE)	33.4%
Return on Capital Employed (ROCE)	38.83%
Total debt to equity ratio	0.18
EBITDA margin	45.29%

Particulars	Mar 25 (₹ value in crores)
Cash and short term investments	₹88.67
Total assets	₹3,031.75
Total liabilities	₹3,031.75
Total equity	₹1,840.64
Shares outstanding	₹25.45
Price to book ratio	₹12.75
Return on assets (%)	8.83%
Return on capital	13.96%

Particulars	Mar 24 (₹ value in crores)
Cash and short term investments	₹50.49
Total assets	₹2,254.08
Total liabilities	₹2,254.08
Total equity	₹2,050.66
Shares outstanding	₹25.45
Price to book ratio	₹8.49
Return on assets (%)	13.32%
Return on capital	14.37%

Particulars	Mar 23 (₹ value in crores)
Cash and short term investments	₹68.01
Total assets	₹1,965.74
Total liabilities	₹1,965.74
Total equity	₹1,735.18
Shares outstanding	₹25.45
Price to book ratio	₹6.88
Return on assets (%)	20.92%
Return on capital	22.79%

Particulars	Mar 22 (₹ value in crores)
Cash and short term investments	₹47.30
Total assets	₹1,829.58
Total liabilities	₹1,829.58
Total equity	₹1,527.18
Shares outstanding	₹25.45
Price to book ratio	₹10.34
Return on assets (%)	24.8%
Return on capital	27.97%

Particulars	Mar 21 (₹ value in crores)
Cash and short term investments	₹9.65
Total assets	₹1,474.47
Total liabilities	₹1,474.47
Total equity	₹1,180.79
Shares outstanding	₹25.45
Price to book ratio	₹11.84
Return on assets (%)	24.57%
Return on capital	27.41%

Particulars	Mar 25 (₹ value in crores)
Cash and short term investments	₹22.62
Total assets	₹2,587.81
Total liabilities	₹2,587.81
Total equity	₹2,315.55
Shares outstanding	₹25.45
Price to book ratio	₹12.75
Return on assets (%)	10.49%
Return on capital	11.39%

Particulars	Mar 24 (₹ value in crores)
Cash and short term investments	₹21.73
Total assets	₹2,214.88
Total liabilities	₹2,214.88
Total equity	₹2,028.35
Shares outstanding	₹25.45
Price to book ratio	₹8.49
Return on assets (%)	13.38%
Return on capital	14.34%

Particulars	Mar 23 (₹ value in crores)
Cash and short term investments	₹46.23
Total assets	₹1,958.33
Total liabilities	₹1,958.33
Total equity	₹1,749.38
Shares outstanding	₹25.45
Price to book ratio	₹6.88
Return on assets (%)	22.09%
Return on capital	23.79%

Particulars	Mar 22 (₹ value in crores)
Cash and short term investments	₹32.95
Total assets	₹1,804.88
Total liabilities	₹1,804.88
Total equity	₹1,520.69
Shares outstanding	₹25.45
Price to book ratio	₹10.34
Return on assets (%)	30.92%
Return on capital	34.53%

Particulars	Mar 21 (₹ value in crores)
Cash and short term investments	₹9.56
Total assets	₹1,358.82
Total liabilities	₹1,358.82
Total equity	₹1,065.18
Shares outstanding	₹25.45
Price to book ratio	₹11.84
Return on assets (%)	22.71%
Return on capital	25.58%

Particulars	Mar 25 (₹ value in crores)
Net income	₹343.92
Cash from operations	₹371.60
Cash from investing	-₹255.30
Cash from financing	₹3.32
Net change in cash	₹36.18
Free cash flow	₹527.31

Particulars	Mar 24 (₹ value in crores)
Net income	₹405.67
Cash from operations	₹468.43
Cash from investing	-₹362.25
Cash from financing	-₹13.80
Net change in cash	-₹17.57
Free cash flow	₹520.22

Particulars	Mar 23 (₹ value in crores)
Net income	₹559.72
Cash from operations	₹602.95
Cash from investing	-₹195.00
Cash from financing	-₹241.95
Net change in cash	₹20.23
Free cash flow	₹888.86

Particulars	Mar 22 (₹ value in crores)
Net income	₹667.58
Cash from operations	₹514.25
Cash from investing	-₹136.20
Cash from financing	-₹156.41
Net change in cash	₹37.38
Free cash flow	₹589.44

Particulars	Mar 21 (₹ value in crores)
Net income	₹467.67
Cash from operations	₹491.98
Cash from investing	-₹311.39
Cash from financing	-₹75.66
Net change in cash	-₹4.51
Free cash flow	₹602.82

Particulars	Mar 25 (₹ value in crores)
Net income	₹351.35
Cash from operations	₹381.41
Cash from investing	-₹320.94
Cash from financing	₹20.81
Net change in cash	₹0.90
Free cash flow	₹520.31

Particulars	Mar 24 (₹ value in crores)
Net income	₹400.42
Cash from operations	₹484.72
Cash from investing	-₹362.40
Cash from financing	-₹39.99
Net change in cash	-₹26.19
Free cash flow	₹536.60

Particulars	Mar 23 (₹ value in crores)
Net income	₹579.39
Cash from operations	₹638.60
Cash from investing	-₹236.86
Cash from financing	-₹243.14
Net change in cash	₹12.81
Free cash flow	₹783.21

Particulars	Mar 22 (₹ value in crores)
Net income	₹722.44
Cash from operations	₹421.63
Cash from investing	-₹90.36
Cash from financing	-₹156.41
Net change in cash	₹23.11
Free cash flow	₹496.82

Particulars	Mar 21 (₹ value in crores)
Net income	₹413.97
Cash from operations	₹439.16
Cash from investing	-₹257.65
Cash from financing	-₹76.55
Net change in cash	-₹4.48
Free cash flow	₹550.00

Company name	Price	P/E	P/B	Market cap	52 week low/high
AMBALAL SARABHAI ENTERPRISES L	₹25.41	12.46	1.31	₹194.73	₹23.12 / ₹53.83
BLISS GVS PHARMA LTD	₹183.50	17.71	1.71	₹1,941.23	₹105.05 / ₹195.85
CIPLA LTD	₹1,330.80	22.61	3.26	₹1,07,499.45	₹1,283.00 / ₹1,672.20
FERMENTA BIOTECH LIMITED	₹328.25	8.62	2.47	₹966.07	₹219.00 / ₹449.00

Company name	Price	P/E	P/B	Market cap	52 week low/high
AMBALAL SARABHAI ENTERPRISES L	₹25.41	12.46	1.31	₹194.73	₹23.12 / ₹53.83
BLISS GVS PHARMA LTD	₹183.50	17.71	1.71	₹1,941.23	₹105.05 / ₹195.85
CIPLA LTD	₹1,330.80	22.61	3.26	₹1,07,499.45	₹1,283.00 / ₹1,672.20
FERMENTA BIOTECH LIMITED	₹328.25	8.62	2.47	₹966.07	₹219.00 / ₹449.00

Cohance Lifesciences Ltd technical summary

₹339.45

-4.86 ▼

Bearish

Bullish

5 Day358.8

10 Day371.5

12 Day376.9

20 Day399.7

26 Day416.5

50 Day483.3

100 Day604

200 Day745

Investment Returns

Over 1 Month32.42%▼

Over 3 Months53.1%▼

Over 6 Months63.73%▼

Over 1 Year70.87%▼

Cohance Lifesciences Ltd Shareholding pattern

Public

14.92%

Promoter holdings

57.48%

FII

6.01%

DII

21.56%

Promoter shares

100%

Promoter shares	Share	Category
Berhyanda Limited	12,75,39,592 (33.34%)	Shareholding of Promoter and Promoter Group
Jusmiral Holdings Limited	9,23,90,578 (24.15%)	Shareholding of Promoter and Promoter Group
Jasti Property And Equity Holdings Private Limited	2,45,31,590 (6.41%)	Public Shareholding
Dsp Regular Savings Fund	1,68,13,753 (4.39%)	Public Shareholding
Hdfc Mutual Fund - Hdfc Manufacturing Fund	1,19,28,059 (3.12%)	Public Shareholding

About COHANCE LIFESCIENCES LTD

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018. The name of the Company has been changed to Cohance Lifesciences Limited w.e.f. May 7, 2025. Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020. The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each. The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21. During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020. As on 31 March 2020,the company has one subsidiary and one associate company under its roof. The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator. The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956.. In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022. During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company. The Company acquired 67.5% stake in Sapala Organics Private Limited, making it a subsidiary of the Company w.e.f. July 12, 2024. The Company acquired 56% equity share capital of NJ Bio, Inc., making it a subsidiary effective from December 20, 2024. The wholly owned subsidiary, Casper Pharma Private Limited was merged into the Company and the Scheme of Amalgamation became effective from January 1, 2025. Similarly, Cohance Lifesciences Limited has merged with and into Suven Pharmaceuticals Limited w.e.f May 1, 2025.

Parent Organisation

Indian Private

NSE Symbol

COHANCE

Founded

2018

COHANCE LIFESCIENCES LTD CORPORATE ACTION

Dividend date	Dividend amount	Dividend type	Record date	Instrument type
09 Sept 2022	5	Special	12 Sept 2022	Equity shares
09 Sept 2022	1	Interim	12 Sept 2022	Equity shares
13 May 2022	1	Special	17 May 2022	Equity shares
13 May 2022	1	Interim 2	17 May 2022	Equity shares
15 Feb 2022	2	Special	16 Feb 2022	Equity shares
15 Feb 2022	1	Interim	16 Feb 2022	Equity shares
13 Aug 2021	1	Final	17 Aug 2021	Equity shares
17 Feb 2021	1	Interim	18 Feb 2021	Equity shares

Ex-date	Ex-bonus	Ratio
28 Sept 2020	25 Sept 2020	1:1

View more stocks

sun pharmaceutical ind l

₹1,695.1

▼ 0.44%

divi s laboratories ltd

₹6,024.5

▼ 1.90%

torrent pharmaceuticals l

₹3,939

▼ 0.94%

cipla ltd

₹1,330

▼ 0.24%

dr. reddy s laboratories

₹1,241.2

▼ 0.29%

lupin limited

₹2,173.7

▼ 2.01%

What’s trending

All stocks

LOYALTEX

LOYAL TEXTILE MILLS LTD.

304.8

+50.8 (+20%)

GORANIN

GORANI INDUSTRIES LTD.

NIRAJ ISPAT IND LTD

STRATMONT INDUSTRIES LIMITED

90.01

+15 (+20%)

View all

Top gainers

ITC LTD

KOTAK MAHINDRA BANK LTD

422.35

+13.60 (+3.33%)

HINDUNILVR

HINDUSTAN UNILEVER LTD.

2424.2

+69.80 (+2.96%)

BHARTIARTL

BHARTI AIRTEL LIMITED

2038.4

+46.00 (+2.31%)

View all

Top losers

HDFC LIFE INS CO LTD

TATA CONSULTANCY SERV LT

2941.6

-49.90 (-1.67%)

TECHM

TECH MAHINDRA LIMITED

BAJAJ AUTO LIMITED

Frequently asked questions

 As of 06/02/2026, at 15:30 PM, the Cohance Lifesciences Ltd share price stands at ₹339.45.

Related tags

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Broking services offered by Bajaj Financial Securities Limited (Bajaj Broking). Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403.

Details of Compliance Officer: Mr. Boudhayan Ghosh (For Broking/DP/Research) | Email: compliance_sec@bajajbroking.in | Contact No.: 020-4857 4486. For any investor grievances write to compliance_sec@bajajbroking.in/ compliance_dp@bajajbroking.in (DP related)

This content is for educational purpose only. Securities quoted are exemplary and not recommendatory.

Research Services are offered by Bajaj Broking as Research Analyst under SEBI Regn: INH000010043.

For more disclaimer, check here: https://www.bajajbroking.in/disclaimer

COHANCE LIFESCIENCES LTD

Cohance lifesciences ltd share price update

Cohance Lifesciences Ltd stock performance

₹334.5

₹355

₹334.5

₹1,328

Cohance Lifesciences Ltd fundamentals

Cohance Lifesciences Ltd financials

Particulars

Sep 25 (₹ value in crores)

Revenue

₹497.79

Operating expense

₹403.37

Net income

₹94.29

Net profit margin

18.94%

Earning per share

₹2.46

EBITDA

₹157.16

Effective tax rate

21.89%

Particulars

Jun 25 (₹ value in crores)

Revenue

₹483.58

Operating expense

₹417.54

Net income

₹52.57

Net profit margin

10.87%

Earning per share

₹1.38

EBITDA

₹109.20

Effective tax rate

25.99%

Particulars

Mar 25 (₹ value in crores)

Revenue

₹768.57

Operating expense

₹595.38

Net income

₹122.77

Net profit margin

15.97%

Earning per share

₹3.22

EBITDA

₹215.18

Effective tax rate

25.86%

Particulars

Dec 24 (₹ value in crores)

Revenue

₹284.27

Operating expense

₹188.55

Net income

₹83.67

Net profit margin

29.43%

Earning per share

₹3.29

EBITDA

₹128.72

Effective tax rate

24.77%

Particulars

Sep 24 (₹ value in crores)

Revenue

₹594.43

Operating expense

₹434.89

Net income